Toronto Stock Exchange Symbol: MS
EDMONTON, May 15 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced financial and operational results for the first quarter ended March 31, 2008. BioMS, in partnership with Eli Lilly and Company, is developing dirucotide (also known as MBP8298), a synthetic peptide drug for the treatment of MS undergoing pivotal trials in Canada, Europe and the US.
"During the quarter, we completed our landmark partnership deal with Eli Lilly and Company," said Kevin Giese, President and CEO of BioMS Medical. "We now look forward to multiple clinical milestones for dirucotide (MBP8298) over the next 24 months. In the near-term, the Data Safety Monitoring Board for our MAESTRO-01 pivotal trial will review data from the first 200 patients in the trial and recommend whether the trial should continue. A positive outcome from this review, anticipated in the third quarter of 2008, is expected to trigger a milestone payment from our new partner."
Currently, BioMS is conducting three clinical trials and one open-label
follow-on trial for dirucotide (MBP8298):
- MAESTRO-01: A pivotal phase II/III trial in Canada and Western Europe
evaluating dirucotide (MBP8298) for the treatment of secondary
progressive MS (SPMS). On January 22, 2007, BioMS announced that the
trial had completed full recruitment of 611 patients at 47 trial
sites in 10 countries. Patients are administered either dirucotide
(MBP8298) or placebo every six months for a period of two years. To
date, there have been eight positive safety reviews from the
Data Safety Monitoring Board (DSMB).
- MAESTRO-02: An open-label follow-on study to the MAESTRO-01 pivotal
trial. Eligible patients who have successfully completed the blinded,
placebo controlled MAESTRO-
|SOURCE BioMS Medical Corp.|
Copyright©2008 PR Newswire.
All rights reserved